AstraZeneca PLC (ZEGA) - Total Assets
Based on the latest financial reports, AstraZeneca PLC (ZEGA) holds total assets worth €114.46 Billion EUR (≈ $133.81 Billion USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore ZEGA debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
AstraZeneca PLC - Total Assets Trend (2014–2024)
This chart illustrates how AstraZeneca PLC's total assets have evolved over time, based on quarterly financial data. See net assets of AstraZeneca PLC for net asset value and shareholders' equity analysis.
AstraZeneca PLC - Asset Composition Analysis
Current Asset Composition (December 2024)
AstraZeneca PLC's total assets of €114.46 Billion consist of 24.8% current assets and 75.2% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 5.3% |
| Accounts Receivable | €8.30 Billion | 8.0% |
| Inventory | €5.29 Billion | 5.1% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €37.18 Billion | 35.7% |
| Goodwill | €21.02 Billion | 20.2% |
Asset Composition Trend (2014–2024)
This chart illustrates how AstraZeneca PLC's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see AstraZeneca PLC market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: AstraZeneca PLC's current assets represent 24.8% of total assets in 2024, a decrease from 28.5% in 2014.
- Cash Position: Cash and equivalents constituted 5.3% of total assets in 2024, down from 10.9% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 55.0% of total assets, an increase from 54.0% in 2014.
- Asset Diversification: The largest asset category is intangible assets at 35.7% of total assets.
AstraZeneca PLC Competitors by Total Assets
Key competitors of AstraZeneca PLC based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biogen Inc
NASDAQ:BIIB
|
USA | $29.44 Billion |
|
Pfizer Inc
SA:PFIZ34
|
Brazil | R$207.62 Billion |
|
AstraZeneca PLC
NYSE:AZN
|
USA | $114.02 Billion |
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SHG:600436
|
China | CN¥18.38 Billion |
|
Aurora Optoelectronics Co Ltd
SHG:600666
|
China | CN¥2.22 Billion |
|
NanJing Pharmaceutical Co Ltd
SHG:600713
|
China | CN¥34.05 Billion |
|
Dimed S.A. Distribuidora de Medicamentos
SA:PNVL3
|
Brazil | R$3.66 Billion |
|
Firebrick Pharma Ltd
AU:FRE
|
Australia | AU$2.28 Million |
AstraZeneca PLC - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.88 | 0.93 | 0.96 |
| Quick Ratio | 0.69 | 0.71 | 0.76 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €-4.11 Billion | €-1.77 Billion | €-763.00 Million |
AstraZeneca PLC - Advanced Valuation Insights
This section examines the relationship between AstraZeneca PLC's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.06 |
| Latest Market Cap to Assets Ratio | 2.43 |
| Asset Growth Rate (YoY) | 2.9% |
| Total Assets | €104.03 Billion |
| Market Capitalization | $252.57 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values AstraZeneca PLC's assets at a significant premium (2.43x), suggesting investors see substantial growth potential or unique competitive advantages.
Positive Asset Growth: AstraZeneca PLC's assets grew by 2.9% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for AstraZeneca PLC (2014–2024)
The table below shows the annual total assets of AstraZeneca PLC from 2014 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €104.03 Billion ≈ $121.63 Billion |
+2.88% |
| 2023-12-31 | €101.12 Billion ≈ $118.22 Billion |
+4.80% |
| 2022-12-31 | €96.48 Billion ≈ $112.80 Billion |
-8.43% |
| 2021-12-31 | €105.36 Billion ≈ $123.18 Billion |
+57.90% |
| 2020-12-31 | €66.73 Billion ≈ $78.01 Billion |
+8.72% |
| 2019-12-31 | €61.38 Billion ≈ $71.76 Billion |
+1.20% |
| 2018-12-31 | €60.65 Billion ≈ $70.91 Billion |
-4.27% |
| 2017-12-31 | €63.35 Billion ≈ $74.07 Billion |
+1.32% |
| 2016-12-31 | €62.53 Billion ≈ $73.10 Billion |
+4.11% |
| 2015-12-31 | €60.06 Billion ≈ $70.21 Billion |
+2.49% |
| 2014-12-31 | €58.59 Billion ≈ $68.50 Billion |
-- |
About AstraZeneca PLC
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo,… Read more